N/A N=9 Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease
Hypertension · Chronic Kidney Diseases
Primary: Change in 24-hour Mean Arterial Pressure (MAP) — 1.4 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=127 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
Pediatric Hypertension With or Without CKD
Primary: Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint — -1.2; -9.2; -6.9; -7.8 mmHg — p=0.0096
N/A N=41,054 Pediatric Blood Pressure Clinical Decision Support Tool (PedsBP CDS)
Hypertension
Primary: Blood Pressure Remeasurement — 245; 829; 1813 participants — p=<0.001
Phase 3 N=33 Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
Hypertension Secondary to Kidney Transplant
Primary: Number of Participants Who Are Non Dippers — 7; 12 Participants
Phase 3 N=35 Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
Hypertension
Primary: Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP). — -2.86 Millimeters of Mercury (mm Hg)
N/A N=35 Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension
Essential Hypertension
Primary: The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy — 16; 8; 4 Participants
N/A N=1,819 Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
Hypertension
Primary: Change in Blood Pressure — -1; -2; -2; -2 mmHg
Phase 3 N=4 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Anaemia
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants
Phase 3 N=208 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study — -7.63; -7.94 millimeter(s) of mercury (mmHg) — p=0.0040
Phase 4 N=14 A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
Chronic Kidney Disease · Poorly-Controlled Hypertension
Primary: Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks — -10.5 mmHg — p=0.01
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 3 N=215 An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
Hypertension
Primary: Change in Seated Diastolic Blood Pressure Between AZM and Placebo — 3.9; -1.6 mmHg
Phase 2 N=162 Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
Chronic Kidney Diseases · Hypertension
Primary: Systolic Blood Pressure — 155.8; 154.3; 155.7; 150.4 mmHg
Phase 3 N=267 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Endpoint (Phase 1) — -5.54; -5.42; -9.03 millimeter(s) of mercury (mmHg)
Phase 1 N=24 Olmesartan Pediatric Pharmacokinetic (PK) Study
Hypertension
Primary: For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t) — 7874; 5851 ng/mL*hr
N/A N=2,026 Electronic Tools to Increase Recognition and Improve Primary Care Management for Hypertension in Chronic Kidney Disease
Chronic Kidney Diseases · Hypertension
Primary: Change in Systolic Blood Pressure (SBP) From Baseline to 180 Days — 14.6; 11.7 mmHg
Phase 3 N=27 A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
Pediatric Hypertension
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 19; 5 Participants
N/A N=781 Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
N/A N=31 Diet and Hypertension Management in African Americans With Chronic Kidney Disease
Chronic Kidney Diseases · High Blood Pressure
Primary: Number of Group Counseling Sessions Attended by Participants Randomized to the Treatment Arm — 8.9 sessions per participant
N/A N=44 Pedometers to Assess and Increase Physical Activity Among Children With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Physical Activity — 73; -133; 100 change in steps per day
Phase 2 N=160 Chlorthalidone in Chronic Kidney Disease
Renal Insufficiency, Chronic · Hypertension
Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg
N/A N=6,295 Chronic Kidney Disease Clinical Decision Support
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Phase 3 N=150 Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
Hypertension · Chronic Kidney Disease
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF) — -13.3; -15.5 millimeter(s) of…
Phase 2 N=39 A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
Hypertension
Primary: Maximum Plasma Concentration (Cmax) at Day 1 and Day 8 in 6-11 and 12-17 Year Old Patients — 76.8; 393.3; 82.2; 397.1 ng/ml
Phase 3 N=101 Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)
Hypertension
Primary: Mean Change From Baseline in Systolic Blood Pressure — -7.31; -7.65; -6.67 mmHg — p=0.753
Phase 2 N=295 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Hyperkalemia · Resistant Hypertension
Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001
Phase 4 N=49 N-of-1 Trials In Children With Hypertension
Pediatric Hypertension
Primary: Number of Participants With Ambulatory Blood Pressure (BP) Control at 6 Months — 8; 8; 10; 15 Participants
N/A N=31,579 Electronic Health Record-Based Clinical Decision Support to Improve Blood Pressure Management in Adolescents
Hypertension · Pre Hypertension · Obesity
Primary: Participants With Clinical Recognition of Hypertension — 160; 51 Participants — p=<.001
Phase 3 N=74 Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6) — -8.3; -10.3; -14.4 mm Hg — p=0.0990
N/A N=342 Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
Safety Issues · Chronic Kidney Diseases
Primary: Change in Renal Function From Baseline to Study Completion; — 0.01; 0.02 mg/dL